Abeona Therapeutics Soars 10.06% on Voucher Sale

Abeona Therapeutics surged 10.06% in pre-market trading on May 12, 2025, marking a significant rise in its stock price.

Abeona Therapeutics announced that it will sell its Priority Review Voucher for $155 million. This move is part of the company's strategy to enhance its financial position and potentially achieve profitability. The sale of the voucher, which allows for expedited review of a new drug application by the FDA, is expected to provide a substantial cash infusion for Abeona Therapeutics.

The company's decision to sell the voucher comes at a time when the market is closely watching its financial performance. The proceeds from the sale will likely be used to support ongoing research and development efforts, as well as to strengthen the company's balance sheet. This strategic move is seen as a positive step towards improving Abeona Therapeutics' financial health and long-term prospects.